Effects of 7 days of treatment with the cannabinoid type 1 receptor antagonist, rimonabant, on emotional processing
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Rimonabant is a cannabinoid type 1 receptor (CB1) antagonist formerly used to treat obesity, but which was withdrawn from the market in late 2008 because of its association with psychiatric adverse effects such as depression and anxiety. Previously, we showed that a single dose of rimonabant produced a negative bias on an emotional word memory task, in the absence of subjective mood effects. The present study investigated whether a similar effect on emotional processing could be seen after 7 days’ daily treatment with rimonabant 20 mg, using a randomized, placebo-controlled, between-subjects design in healthy volunteers (final n = 21). In comparison with placebo, rimonabant induced a negative bias on a memory recognition task without producing a change in subjective mood. This raises the possibility that the depressogenic effects of rimonabant may be linked to emotional memory biases, and that such biases may be detectable in the absence of subjective mood changes. Investigating such effects could be useful in detecting adverse psychiatric effects of novel treatments.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Interestingly, in healthy volunteers rimonabant, after a single dose and 7 days of treatment, was shown to have an effect opposite to what would be expected of an AD drug. It reduced positive bias, decreased the number of false recollections of positive words (Horder et al. 2012), and decreased the recall of positive words, with no effect on negative words (Horder et al. 2009).”
From Cognitive neuropsychological theory of antidepressant action: a modern-day approach to depression and its treatment (2021) · cites this paper as Horder et al. 2012
In the citing paper
“Further evidence to corroborate this possibility comes from studies considering the effects of the cannabinoid antiobesity agent rimonabant, which found that both single and repeated (7 days) dosing with this agent resulted in negative biases emotional memory.76,77”
From The effects of drugs on human models of emotional processing: an account of antidepressant drug treatment (2015) · cites this paper as [76]
Citations
Cites
Ekman, P. (1976) · Medical Entomology and Zoology · Cited by 4,345
Cognitive vulnerability to emotional disorders
Mathews, A., & MacLeod, C. (2005) · Annual Review of Clinical Psychology · doi:10.1146/annurev.clinpsy.1.102803.143916 · Cited by 2,100 · cited 2×
“This effect is consistent with the idea that chronic treatment with rimonabant produces a negative bias in an aspect of emotional memory which is sensitive to depression (Mathews and MacLeod, 2005).”
BackgroundResultLikableness ratings of 555 personality-trait words.
Anderson, N. H. (1968) · Journal of Personality and Social Psychology · doi:10.1037/h0025907 · Cited by 1,638 · cited 1×
“A total of 60 personality characteristic words selected to be extremely disagreeable (e.g. domineering, untidy, hostile) or agreeable (cheerful, honest, optimistic) (taken from Anderson, 1968) were presented on the computer screen for 500ms.”
BackgroundThe Evolution of the Cognitive Model of Depression and Its Neurobiological Correlates
Beck, A. T. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08050721 · Cited by 1,537 · cited 2×
“The increased accessibility of negative perceptions and memories is believed to maintain and exaggerate depressed mood, while itself being a product of the depressed mood state, leading to a self-perpetuating cycle (Beck, 2008).”
BackgroundEfficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials
Christensen, R., Kristensen, P. K., Bartels, E. M., Bliddal, H., & Astrup, A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61721-8 · Cited by 1,097 · cited 2×
“5 times more likely to discontinue the treatment because of depressive mood disorders than were those given placebo’’ (Christensen et al., 2007).”
BackgroundInfluentialHarmer, C. J., Goodwin, G. M., & Cowen, P. J. (2009) · British Journal of Psychiatry · doi:10.1192/bjp.bp.108.051193 · Cited by 542 · cited 5×
“effects of antidepressant drug agents in this task (Harmer et al., 2009).”
BackgroundResultSelf-citationFacial expression megamix: Tests of dimensional and category accounts of emotion recognition
Young, A. W., Rowland, D., Calder, A. J., Etcoff, N. L., Seth, A., & Perrett, D. I. (1997) · Cognition · doi:10.1016/s0010-0277(97)00003-6 · Cited by 539 · cited 1×
“The facial expression recognition task featured six basic emotions (happiness, surprise, sadness, fear, anger and disgust) taken from the Pictures of Affect Series (Ekman and Friesen, 1976), which had been morphed between each prototype and neutral (Young et al., 1997).”
MethodFacial emotion discrimination: II. Behavioral findings in depression
Gur, R. C., Erwin, R. J., Gur, R. E., Zwil, A. S., Heimberg, C., & Kraemer, H. C. (1992) · Psychiatry Research · doi:10.1016/0165-1781(92)90116-k · Cited by 500 · cited 1×
“Also, depressed patients are more likely to perceive ambiguous facial expressions as negative compared with controls (Bouhuys et al., 1999; Gur et al., 1992).”
BackgroundThe effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety
Haller, J., Bakos, N., Szirmay, M., Ledent, C., & Freund, T. F. (2002) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2002.02192.x · Cited by 354 · cited 2×
“, 1997) and decreases (Griebel et al., 2005; Haller et al., 2002) in anxiety being observed in different studies.”
BackgroundNavarro, M., Hernández, E., Muñoz, R. M., del Arco, I., Villanúa, M. A., Carrera, M. R. A., & Rodríguez de Fonseca, F. (1997) · NeuroReport · doi:10.1097/00001756-199701200-00023 · Cited by 306 · cited 2×
“In rodent models of anxiety, conflicting results have been obtained with both increases (Navarro et al., 1997) and decreases (Griebel et al., 2005; Haller et al., 2002) in anxiety being observed in different studies.”
BackgroundImplicit and explicit memory for emotion-congruent information in clinical depression and anxiety
Bradley, B. P., Mogg, K., & Williams, R. (1995) · Behaviour Research and Therapy · doi:10.1016/0005-7967(95)00029-w · Cited by 291 · cited 2×
“primed lexical decision) memory paradigms (Bradley et al., 1995).”
BackgroundImprovement of memory in rodents by the selective CB1 cannabinoid receptor antagonist, SR 141716
Terranova, J. P., Storme, J. J., Lafon, N., Pério, A., Rinaldi-Carmona, M., Le Fur, G., & Soubrié, P. (1996) · Psychopharmacology · doi:10.1007/bf02246352 · Cited by 283 · cited 2×
“…data from preclinical animal studies in which both antidepressant-like effects in rodent models of depression (see Introduction) and enhanced memory processes in a number of species (Lichtman, 2000; Shiflett et al., 2004; Terranova et al., 1996) are seen following acute rimonabant administration.”
BackgroundResultGriebel, G., Stemmelin, J., & Scatton, B. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.10.032 · Cited by 253 · cited 3×
“, 1997) and decreases (Griebel et al., 2005; Haller et al., 2002) in anxiety being observed in different studies.”
BackgroundResultThe psychiatric side-effects of rimonabant
Moreira, F. A., & Crippa, J. A. S. (2009) · Revista Brasileira de Psiquiatria · doi:10.1590/s1516-44462009000200012 · Cited by 235 · cited 1×
“It was approved in Europe in 2006 for the treatment of obesity, but in early 2009 the licensing authorization was withdrawn due to the occurrence of psychiatric side effects, including depression, anxiety and suicidal ideation (Le Foll et al., 2009; Moreira and Crippa, 2009).”
BackgroundBOUHUYS, A. L., GEERTS, E., & GORDIJN, M. C. M. (1999) · The Journal of Nervous & Mental Disease · doi:10.1097/00005053-199910000-00002 · Cited by 235 · cited 1×
“Also, depressed patients are more likely to perceive ambiguous facial expressions as negative compared with controls (Bouhuys et al., 1999; Gur et al., 1992).”
BackgroundSR 141716A enhances spatial memory as assessed in a radial-arm maze task in rats
Lichtman, A. H. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00615-4 · Cited by 171 · cited 2×
“…data from preclinical animal studies in which both antidepressant-like effects in rodent models of depression (see Introduction) and enhanced memory processes in a number of species (Lichtman, 2000; Shiflett et al., 2004; Terranova et al., 1996) are seen following acute rimonabant administration.”
BackgroundResultHuestis, M. A., Boyd, S. J., Heishman, S. J., Preston, K. L., Bonnet, D., Le Fur, G., & Gorelick, D. A. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0861-5 · Cited by 167
The future of endocannabinoid-oriented clinical research after CB1 antagonists
Le Foll, B., Gorelick, D. A., & Goldberg, S. R. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1506-7 · Cited by 167 · cited 1×
“It was approved in Europe in 2006 for the treatment of obesity, but in early 2009 the licensing authorization was withdrawn due to the occurrence of psychiatric side effects, including depression, anxiety and suicidal ideation (Le Foll et al., 2009; Moreira and Crippa, 2009).”
BackgroundDepression-like phenotype following chronic CB1 receptor antagonism
Beyer, C. E., Dwyer, J. M., Piesla, M. J., Platt, B. J., Shen, R., Rahman, Z., Chan, K., Manners, M. T., Samad, T. A., Kennedy, J. D., et al. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.03.020 · Cited by 160 · cited 1×
“More recently, it has been reported that longer-term (21 days) daily treatment with rimonabant did, in fact, produce depression-like effects in a number of behavioural and neurochemical models in rats (Beyer et al., 2010).”
BackgroundA therapeutic role for cannabinoid CB1 receptor antagonists in major depressive disorders
Witkin, J. M., Tzavara, E. T., Davis, R. J., Li, X., & Nomikos, G. G. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.10.006 · Cited by 119 · cited 2×
“, 2005), which led to suggestions that CB1 antagonists might even have clinical utility as antidepressants (Witkin et al., 2005).”
BackgroundResultHorder, J., Harmer, C. J., Cowen, P. J., & McCabe, C. (2010) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710000453 · Cited by 88 · cited 2×
“A full account of the data on the subjective state effects has been published previously (Horder et al., 2010).”
BackgroundSelf-citationGeorge, D. T., Herion, D. W., Jones, C. L., Phillips, M. J., Hersh, J., Hill, D., Heilig, M., Ramchandani, V. A., Geyer, C., Spero, D. E., et al. (2010) · Psychopharmacology · doi:10.1007/s00213-009-1704-3 · Cited by 74 · cited 2×
“Other short-term studies of rimonabant have likewise reported no mood changes with rimonabant 40mg for 15 days (Huestis et al., 2007) or after rimonabant 20mg for 14 days (George et al., 2009).”
BackgroundHorder, J., Cowen, P. J., Di Simplicio, M., Browning, M., & Harmer, C. J. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1517-4 · Cited by 69 · cited 4×
“However, we have previously shown that a single dose of rimonabant impairs positive affective memory in healthy volunteers (Horder et al., 2009), an effect similar to that seen in depression and opposite to University Department of Psychiatry, Neurosciences Building, Warneford Hospital, Oxford, UK.”
MethodResultSelf-citationOrganization of central synapses by adhesion molecules
Tallafuß, A., Constable, J. R. L., & Washbourne, P. (2010) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2010.07340.x · Cited by 53 · cited 1×
“The dose of 20mg/day was that at which rimonabant was used clinically and was the dose associated with high rates of depression and anxiety in clinical trials, even though it has been suggested that this dose produces only partial blockade of CB1 receptors (Tallafuss et al., 2010).”
BackgroundCannabinoid inhibition improves memory in food–storing birds, but with a cost
Shiflett, M. W., Rankin, A. Z., Tomaszycki, M. L., & DeVoogd, T. J. (2004) · Proceedings of the Royal Society B Biological Sciences · doi:10.1098/rspb.2004.2823 · Cited by 41 · cited 2×
“…data from preclinical animal studies in which both antidepressant-like effects in rodent models of depression (see Introduction) and enhanced memory processes in a number of species (Lichtman, 2000; Shiflett et al., 2004; Terranova et al., 1996) are seen following acute rimonabant administration.”
BackgroundResultAntidepressant drug action: a neuropsychological perspective
Harmer, C. J. (2010) · Depression and Anxiety · doi:10.1002/da.20680 · Cited by 35 · cited 2×
“This would be consistent with our hypothesis (Harmer, 2010) that the mood effects of certain psychotropic drugs are mediated through effects on the processing of emotional information in the absence of any changes in subjective state, and that these effects on emotional processing may be a key…”
ResultSelf-citation
Research works printed but not linked: 1
- Rey A, 1964, L’examen de clinique en psychologie
Cited by
Neurobiological Interactions Between Stress and the Endocannabinoid System
Morena, M., Patel, S., Bains, J. S., & Hill, M. N. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2015.166 · Cited by 660
“…that administration of rimonabant can directly potentiate stress-induced anxiety (Bergamaschi et al, 2014), promote negative memory bias (Horder et al, 2012), suppress positive memory recall (Horder et al, 2009), and dampen activation of reward circuits in the brain in response to…”
BackgroundMayo, L. M., Asratian, A., Lindé, J., Morena, M., Haataja, R., Hammar, V., Augier, G., Hill, M. N., & Heilig, M. (2020) · Biological Psychiatry · doi:10.1016/j.biopsych.2019.07.034 · Cited by 207
Hill, M. N., & Patel, S. (2013) · Biology of Mood & Anxiety Disorders · doi:10.1186/2045-5380-3-19 · Cited by 111
“Similarly, both a single dose of rimonabant, as well as a 7-day treatment regimen of rimonabant, were not found to affect mood significantly, per se, but they were found to suppress the recall of emotionally positive memories [108] and promote negative bias in memory recall [109].”
BackgroundGodlewska, B. R., & Harmer, C. J. (2021) · Psychopharmacology · doi:10.1007/s00213-019-05448-0 · Cited by 123
Self-citationBossong, M. G., van Hell, H. H., Jager, G., Kahn, R. S., Ramsey, N. F., & Jansma, J. M. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.06.009 · Cited by 107
“All rights reserved.”
Metadata
- Authors
- Horder, J., Browning, M., Di Simplicio, M., Cowen, P. J., & Harmer, C. J.
- Affiliations
- Warneford Hospital (GB)
- University Department of Psychiatry, Neurosciences Building, Warneford Hospital, Oxford, UK.
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2011-03-15
- Volume
- 26
- Issue
- 1
- Pages
- 125-132
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W2044385528
- Cited by
- 48
- References
- 26
- Citations by year
- 2025: 2 · 2024: 1 · 2022: 2 · 2021: 1 · 2020: 4 · 2019: 2 · 2018: 3 · 2017: 5 · 2016: 2 · 2015: 9 · 2014: 6 · 2013: 5 · 2012: 6
- FWCI
- 3.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Journal of Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- H. Lundbeck A/S
- Medical Research Council
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- rimonabant, emotional processing, recognition memory, subjective mood, depression, anxiety, psychiatric adverse effects, healthy volunteers
- MeSH terms
- Rimonabant, Adult, Anxiety Disorders, Depression, Emotions, Female, Humans, Male, Memory, Short-Term, Piperidines, Pyrazoles, Recognition, Psychology, Receptor, Cannabinoid, CB1, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.